⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1259162 | 1.00 | — | — | |
| SCHEMBL178594 | 1.00 | — | — | |
| SCHEMBL23670831 | 1.00 | — | — | |
| SCHEMBL2895289 | 1.00 | — | — | |
| SCHEMBL733245 | 0.95 | CA1 (0.46) | — | |
| SCHEMBL23671027 | 0.95 | CA1 (0.46) | — | |
| SCHEMBL733247 | 0.95 | CA1 (0.46) | — | |
| SCHEMBL23670184 | 0.95 | CA1 (0.46) | — | |
| SCHEMBL733246 | 0.95 | CA1 (0.46) | — | |
| SCHEMBL12976066 | 0.93 | CA1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116813596-A | Macrocyclic HCV NS3 inhibits tripeptide synthesis | 吉利德科学公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-111320610-B | Macrocyclic HCV NS3 inhibits tripeptide synthesis | 吉利德科学公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-111320610-A | Macrocyclic HCV NS3 inhibits the synthesis of tripeptides | 吉利德制药有限责任公司 | 2020-06-23 | — | — | CN | disclosed |
| CN-105849118-B | Macrocyclic HCV NS3 inhibits the synthesis of tripeptides | 吉利德制药有限责任公司 | 2020-03-31 | — | — | CN | disclosed |
| EP-3087085-B1 | SYNTHESIS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE | GILEAD SCIENCES INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3087086-B1 | CRYSTALLINE FORMS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE | GILEAD SCIENCES INC (US) | 2018-11-07 | — | — | EP | disclosed |
| US-10030033-B2 | Synthesis of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-9862728-B2 | Crystalline forms of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170267694-A1 | CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND | GILEAD PHARMASSET LLC | 2017-09-21 | — | — | US | disclosed |
| US-20170210756-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. | 2017-07-27 | — | — | US | disclosed |
| US-20150175625-A1 | CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-8461107-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461107-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110046161-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2011-02-24 | — | — | US | disclosed |
| US-20110046161-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2011-02-24 | — | — | US | disclosed |
| EP-2271345-A1 | HCV NS3 PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009134624-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134624-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2000013690-A1 | EXOCYCLIC-PHOSPHOETHANOLAMINES | CLARION PHARMACEUTICALS, INC. (US) | 2000-03-16 | — | — | WO | disclosed |
| US-5804569-A | ANTIINFLAMMATORY, ANTIARRHYMIC AND LOCAL ANESTHETIC AGENT | CLARION PHARMACEUTICALS INC. (US) | 1998-09-08 | — | — | US | disclosed |